Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.81 ▼ -0.03
(-3.13%)
MKT CAP: $36.0M • VOL: 56.0K
52W L $1 52W H $1
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$1
MEDIAN
$1
MEAN
$1
HIGH
$1
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ELUT TAPE
ELUT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $0.98 | $0.93 | 2025-02-14 | $0.74 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1.02 | $0.96 | 2025-02-06 | $0.76 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $0.92 | $0.89 | 2025-01-29 | $0.78 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $0.83 | — | 2025-01-17 | $0.79 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $0.71 | $0.77 | 2025-01-09 | $0.72 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $0.96 | $0.84 | 2024-12-18 | $0.70 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $0.79 | $0.82 | 2024-12-04 | $0.75 | -4.3% | 48% | C |